Carmat's Insolvency, FDA's ADHD Drug Warning, and More: Key Health News Updates
This summary encapsulates recent health updates including Carmat's insolvency filing, Bayer's glyphosate litigation in the U.S. Supreme Court, FDA's label revisions for ADHD stimulants, a U.S. House subpoena over Pfizer's vaccine delay, Moderna's flu shot efficacy, and Torrent Pharma's acquisition of JB Chem's stake.
In recent developments within the health sector, French heart prosthesis company Carmat has filed for insolvency due to a failure in securing necessary emergency funds. In response, trading of Carmat shares has been halted as the Versailles Economic Affairs Court deliberates on the company's future.
In legal news, Bayer is facing further delays in its ongoing glyphosate litigation. The U.S. Supreme Court has requested an opinion from the solicitor general regarding the Durnell case, which could impact Bayer's weedkiller-related lawsuits.
On pharmaceutical fronts, the U.S. FDA is updating ADHD stimulant labels to warn of the potential risk of weight loss in children under six. Additionally, the U.S. House Judiciary Committee has subpoenaed a former Pfizer executive regarding potential delays in COVID-19 vaccine trials, while Moderna has reported their flu shot's superior efficacy against a GSK rival in a late-stage study.
(With inputs from agencies.)
Google News